Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $43.50.
Several analysts have issued reports on AADI shares. Zacks Investment Research lowered Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, January 25th. HC Wainwright dropped their price objective on Aadi Bioscience from $49.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, April 11th. Finally, Piper Sandler dropped their price objective on Aadi Bioscience from $50.00 to $30.00 in a research note on Thursday, May 12th.
NASDAQ AADI traded up $0.44 during trading hours on Monday, hitting $14.79. 57,030 shares of the company traded hands, compared to its average volume of 116,821. The business’s 50-day moving average is $16.22 and its 200-day moving average is $19.70. Aadi Bioscience has a twelve month low of $11.00 and a twelve month high of $49.80.
In other Aadi Bioscience news, insider Neil Desai sold 3,550 shares of the firm’s stock in a transaction on Friday, March 18th. The stock was sold at an average price of $20.07, for a total transaction of $71,248.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.10% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Aadi Bioscience during the 1st quarter worth $683,000. Royal Bank of Canada acquired a new stake in shares of Aadi Bioscience in the 1st quarter valued at $49,000. Goldman Sachs Group Inc. acquired a new stake in shares of Aadi Bioscience in the 1st quarter valued at $1,011,000. State Street Corp boosted its holdings in shares of Aadi Bioscience by 72.0% in the 1st quarter. State Street Corp now owns 535,578 shares of the company’s stock valued at $9,089,000 after purchasing an additional 224,178 shares in the last quarter. Finally, Eversept Partners LP acquired a new stake in shares of Aadi Bioscience in the 1st quarter valued at $2,559,000. Hedge funds and other institutional investors own 62.56% of the company’s stock.
Aadi Bioscience Company Profile (Get Rating)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.
- Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.